Direct Healthcare Professional Communication (DHPC) on Veoza (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
2025.01.13
Active substance: fezolinetant
The marketing authorisation holder of Veoza (fezolinetant) would like to inform about the risk of drug-induced liver injury. Liver function tests must be performed before and during treatment. Patients must be advised to immediately seek medical attention if they experience signs or symptoms that may suggest liver injury such as fatigue, pruritus, jaundice, dark urine, pale faeces, nausea, vomiting, decreased appetite and/or abdominal pain.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN